AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
Read More
